Stefania Bonaccorso

Dr. Stefania Bonaccorso

C&I Foundation Trust, Visiting Lecturer at Dept. of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, UK
Consultant Psychiatrist, Associate Clinical Director, Co-Dir...

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in NeuroToxicology
Verified
Journal Article
Closed access
SBStefania Bonaccorso
Stefania Bonaccorso
ARAngelo Ricciardi
Angelo Ricciardi
CZCaroline Zangani
Caroline Zangani
SCStefania Chiappini
Stefania Chiappini
FSFabrizio Schifano
Fabrizio Schifano

15 April 2015 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
SBStefania Bonaccorso
Stefania Bonaccorso
MSMonsheel Sodhi
Monsheel Sodhi
JLJiang Li
Jiang Li
WBWilliam V Bobo
William V Bobo
YCYuejin Chen
Yuejin Chen
HMHerbert Y Meltzer
Herbert Y Meltzer

1 October 2014 in Schizophrenia Research
Verified
Journal Article
Closed access
CTChristos Theleritis
Christos Theleritis
HFHelen L. Fisher
Helen L. Fisher
ISIngo Shäfer
Ingo Shäfer
LWLaura Winters
Laura Winters
DSDaniel Richard Stahl
Daniel Richard Stahl
SBStefania Bonaccorso
Stefania Bonaccorso

14 July 2018 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SBStefania Bonaccorso
Stefania Bonaccorso
AMAntonio Metastasio
Antonio Metastasio
ARAngelo Ricciardi
Angelo Ricciardi
NSNeil Stewart
Neil Stewart
LJLeila Jamal
Leila Jamal
Fabrizio SchifanoFabrizio Schifano
Fabrizio Schifano
Background: Novel Psychoactive Substances (NPS) are a heterogeneous class of synthetic molecules including synthetic cannabinoid receptor agonists (SCRAs). Psychosis is associated with SCRAs use. There is limited knowledge regarding the structured assessment and psychometric evaluation of clinical presentations, analytical toxicology and clinical management plans of patients presenting with psychosis and SCRAs misuse. Methods: We gathered information regarding the clinical presentations, toxicology and care plans of patients with psychosis and SCRAs misuse admitted to inpatients services. Clinical presentations were assessed using the PANSS scale. Vital signs data were collected using the National Early Warning Signs tool. Analytic chemistry data were collected using urine drug screening tests for traditional psychoactive substances and NPS. Results: We described the clinical presentation and management plan of four patients with psychosis and misuse of SCRAs. Conclusion: The formulation of an informed clinical management plan requires a structured assessment, identification of the index NPS, pharmacological interventions, increases in nursing observations, changes to leave status and monitoring of the vital signs. The objective from using these interventions is to maintain stable physical health whilst rapidly improving the altered mental state.

22 April 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Fabrizio SchifanoFabrizio Schifano
Fabrizio Schifano
SBStefania Bonaccorso
Stefania Bonaccorso
DADavide Arillotta
Davide Arillotta
Amira GuirguisAmira Guirguis
Amira Guirguis
John Martin CorkeryJohn Martin Corkery
John Martin Corkery
NSNicolo' Schifano
Nicolo' Schifano
Background: “Chemsex” involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, “poppers”, type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules as well, to enhance and prolong sexual experiences. This paper aims to provide an overview of the clinical pharmacology of the vast range of drugs that are being used for chemsex with a focus on both the medical and psychopathological disturbances that they can produce. Methods: A narrative literature review was conducted using Pubmed, Scopus, and Web of Science databases. A total of 273 papers published up to January 2025 were screened; articles were selected based on relevance to chemsex/sexualized used behaviour and related substances. Both human and preclinical studies were considered. Results: The use of stimulants is likely related to the need to increase as much as possible both sexual arousal and performance but also to increase social interactions. Furthermore, the empathogenic/entactogenic activities of some MDMA-like “love drugs” facilitate the occurrence of “feeling closer/more intimate” emotional sensations, and GHB/GBL may provide the user with a subjective sensation of disinhibition, hence facilitating condomless meetings with a higher number of random partners. Conversely, ketamine may be used to both enjoy its psychotropic dissociative characteristics and facilitate the potentially painful receptive anal intercourse and/or fisting experiences. Most typically, these drugs are consumed in combination, with polydrug exposure possibly facilitating the occurrence of serotonergic syndrome, seizures, drug–drug pharmacokinetics’ interaction, and sympathomimetic overstimulation. Following these polydrug exposures, a range of psychopathological conditions have at times been reported. These issues may lead to misuse of opiates/opioids, gabapentinoids, and/or antipsychotics. Conclusions: Further actions should aim at reducing the stigma that prevents individuals from accessing necessary healthcare and support services. A multidisciplinary approach that combines medical, psychological, and social support remains key to managing the complex challenges posed by chemsex-related drug use.

23 April 2019 in Current Addiction Reports
Verified
Journal Article
Closed access
PDF file
Fabrizio SchifanoFabrizio Schifano
Fabrizio Schifano
FNFlavia Napoletano
Flavia Napoletano
SCStefania Chiappini
Stefania Chiappini
Laura OrsoliniLaura Orsolini
Laura Orsolini
Amira GuirguisAmira Guirguis
Amira Guirguis
AVAlessandro Vento
Alessandro Vento